NUSCIENCE GROUP
InactiveOverview
Overview
Official details
Source: KBO- Status
- Absorbed by Nuscience Belgium merger by absorption, January 2025
- Activity
- No activity registered in the KBO
- Financial year end
- 31 December
- Peppol
- Not found in the Peppol Directory
Board and ownership
Board
- Philippe van TroostDaily manager
- Jolanda Van HaarlemDirector · since 10-11-2023
- Auditor
- EY Bedrijfsrevisoren BV
Shareholders
- Agrifirm Groupconsolidatesannual accounts 2024
- Holdings
- Shares in 6 companies including Nuscience Iberica s.a.u. and Nuscience Italia Srl
Financial position
No score
Annual accounts 2024
- Turnover
- €41,747
- ▲ 45×
- Operating revenue
- €3.6m
- ▼ 24.2%
- Loss
- €9.4m
- ▲ 152%
- Equity
- €84.1m
- ▼ 10.1%
- Total assets
- €85.5m
- ▼ 9.7%
- Employees on 31-12-2024
- 12
- ▼ 14.3%
Net result -152%: absorbed
Financials
Financials · financial year 2024, full format
Annual accounts 2024 filed on 20-06-2025 PDF all 24 filings
Turnover
€41,747▲ 45×
2023 · €925
EBIT margin
Not meaningful: turnover is only a small part of operating income
Net result
-€9.4m▼ 152%
2023 · -€3.8m
Working capital
€3.0m
2023 · -€402,079
Multi-year overview
2018 to 2024, 6 financial yearsTurnover
€41,747
▲ 45×
2024
20182024
Operating result
€210,798
▼ 7.9%
2024
20182024
Net result
-€9.4m
▼ 152%
2024
20182024
Equity
€84.1m
▼ 10.1%
2024
20182024
Total assets
€85.5m
▼ 9.7%
2024
20182024
Debt
€1.4m
▲ 19.8%
2024
20182024
Working capital
€3.0m
2024
20182024
Staff (FTE)
12.2
▼ 21.3%
2024
20182024
Every figure per financial year
Every figure with its change against the financial year before
favourable
unfavourable
Line201820202021202220232024
Turnover€0.001m€0.04m▲ 45×
Operating result€10.7m-€0.05m-€0.04m▼ 14.4%-€0.06m€0.2m€0.2m▼ 7.9%
Net result€16.8m-€0.002m-€13.9m▲ 8,043×€3.3m▼ 76.1%-€3.8m-€9.4m▼ 152%
Equity€104.7m-€93.3m-€94.0m▲ 0.7%€97.3m▲ 3.5%€93.5m▼ 3.9%€84.1m▼ 10.1%
Total assets€113.2m-€112.4m-€109.9m▼ 2.2%€99.1m▼ 9.8%€94.7m▼ 4.4%€85.5m▼ 9.7%
Debt€8.5m-€19.1m-€15.9m▼ 16.7%€1.9m▼ 88.3%€1.2m▼ 35.4%€1.4m▲ 19.8%
Working capital€5.6m-€0.6m-€1.5m▲ 127%-€0.6m-€0.4m▲ 33.4%€3.0m
Staff (FTE)25.3-24.4-22.6▼ 7.4%19▼ 15.9%15.5▼ 18.4%12.2▼ 21.3%
The operating result for 2024 is 8% lower than in 2023.
Large changes and their cause
- 2024 Net result -152% on 2023. Last accounts before the absorption by Nuscience Belgium (effective 01-01-2025).
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Assets €85.5m
Fixed assets
€81.1m ▼ 13.6%
Current assets
€4.4m ▲ 453%
Equity and liabilities €85.5m
Equity
€84.1m ▼ 10.1%
Debt
€1.4m ▲ 19.8%
Debt's share of the balance-sheet total rises from 1.3% to 1.7%. Equity is lower and debt is higher.
Key figures and ratios
EBITDA
€218,384▼
2023 · €229,906
Cash flow
-€9.4m▼
2023 · -€3.7m
Current ratio
3.06▲
2023 · 0.66
Debt to equity
0.02▲
2023 · 0.01
ROE
-11.2%▼
2023 · -4.0%
ROA
-11.0%▼
2023 · -4.0%
Interest coverage
44.50▲
2023 · 28.20
Debt ≤ 1 year
€1.4m▲
2023 · €1.2m
Income taxes
€158,540▼
2023 · €223,988
Customer credit
1431 days▼
2023 · 16112 days
Staff costs
€1.8m▼
2023 · €2.0m
Green means a favourable move, even when the figure itself falls, as with debt or debt to equity.
Staff
| Item | 31-12-2022 | 31-12-2023 | 31-12-2024 |
|---|---|---|---|
| Employees at the balance-sheet date | 18 | 14 | 12 |
| full-time | 15 | 11 | 9 |
| part-time | 3 | 3 | 3 |
| in full-time equivalents | 17.4 | 13.4 | 11.4 |
| Average over the year, in full-time equivalents | 19 | 15.5 | 12.2 |
| On a permanent contract | 18 | 14 | 12 |
| Joined | 0 | 0 | 0 |
| Left | 4 | 4 | 2 |
| Training hours | 358 | - | - |
Source: social balance sheet in the 2022 to 2024 annual accounts
Investments
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Tangible fixed assets | - | €9,582 | - | - |
| Financial fixed assets | - | €6.0m | - | - |
| Depreciation and write-downs of the year | €42,362 | €2,510 | €957 | €7,586 |
Source: notes to the 2021 to 2024 annual accounts (statement of fixed assets)
Auditor
The auditor is EY Bedrijfsrevisoren BV.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Fee for the audit | €2,000 | €2,120 | €3,000 | €2,380 |
Source: notes to the 2021 to 2024 annual accounts (relations with the auditor)
Annual accounts
| Line | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|---|
| Operating income70/76A | - | - | €6.1m | €5.0m | €4.7m | €3.6m | ▼ 24.2% |
| Turnover70 | - | - | - | - | €0.001m | €0.04m | ▲ 45× |
| Other operating income74 | - | - | €6.1m | €5.0m | €4.7m | €3.5m | ▼ 25.1% |
| Operating charges60/66A | - | - | €6.1m | €5.1m | €4.5m | €3.4m | ▼ 25.1% |
| Services and other goods61 | - | - | €2.9m | €2.5m | €2.4m | €1.6m | ▼ 35.1% |
| Remuneration, social security and pensions62 | - | - | €3.2m | €2.5m | €2.0m | €1.8m | ▼ 12.6% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €0.5m | €0.3m | €0.04m | €0.003m | €0.001m | €0.008m | ▲ 692% |
| Other operating charges640/8 | - | - | €0.02m | €0.01m | €0.03m | €0.007m | ▼ 77.5% |
| Operating profit (loss)9901 | €10.7m | €0.05m | €0.04m | -€0.06m | €0.2m | €0.2m | ▼ 7.9% |
| Financial income75/76B | - | - | - | €4.4m | €0.2m | €3.3m | ▲ 16× |
| Recurring financial income75 | €8.1m | €16.5m | €15.0m | €4.4m | €0.002m | €3.3m | ▲ 1,408× |
| Income from financial fixed assets750 | - | - | €15.0m | €4.3m | €0.002m | €3.3m | ▲ 1,544× |
| Income from current assets751 | - | - | €0.004m | - | - | €0 | - |
| Other financial income752/9 | - | - | €0.01m | €0.06m | €220 | €0.02m | ▲ 92× |
| Non-recurring financial income76B | - | - | - | - | €0.2m | - | - |
| Financial charges65/66B | - | - | €0.05m | €1.0m | €4.0m | €12.8m | ▲ 223% |
| Recurring financial charges65 | €0.8m | €0.5m | €0.05m | €0.006m | €0.02m | €0.01m | ▼ 26.0% |
| Debt charges650 | €0.3m | €0.006m | €0.005m | €0.004m | €0.008m | €0.005m | ▼ 39.8% |
| Write-downs on current assets other than stocks, contracts in progress and trade receivables: additions (reversals)651 | - | - | €0.006m | - | - | €0 | - |
| Other financial charges652/9 | - | - | €0.03m | €0.003m | €0.008m | €0.007m | ▼ 11.6% |
| Non-recurring financial charges66B | - | - | - | €1.0m | €4.0m | €12.8m | ▲ 224% |
| Profit (loss) for the period before taxes9903 | €17.6m | €0.006m | €15.0m | €3.3m | -€3.5m | -€9.3m | ▼ 163% |
| Income taxes67/77 | €0.8m | €0.004m | €1.2m | €0.03m | €0.2m | €0.2m | ▼ 29.2% |
| Taxes670/3 | - | - | €1.2m | €0.03m | €0.2m | €0.2m | ▼ 29.2% |
| Tax adjustments and reversals of tax provisions77 | - | - | - | - | - | €0 | - |
| Profit (loss) for the period9904 | €16.8m | €0.002m | €13.9m | €3.3m | -€3.8m | -€9.4m | ▼ 152% |
| Profit (loss) for the period to be appropriated9905 | €16.8m | €0.002m | €13.9m | €3.3m | -€3.8m | -€9.4m | ▼ 152% |
| Line | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Total assets20/58 | €113.2m | €112.4m | €109.9m | €99.1m | €94.7m | €85.5m | ▼ 9.7% |
| Fixed assets21/28 | €99.4m | €92.7m | €92.5m | €97.9m | €93.9m | €81.1m | ▼ 13.6% |
| Intangible fixed assets21 | €0.7m | €0.04m | €0.002m | - | - | - | - |
| Tangible fixed assets22/27 | €0.03m | €0.002m | €134 | €0.01m | €0.009m | €0.001m | ▼ 88.8% |
| Land and buildings22 | - | - | - | - | €0 | - | - |
| Furniture and vehicles24 | - | - | €134 | - | - | - | - |
| Other tangible fixed assets26 | - | - | - | €0.01m | €0.009m | €0.001m | ▼ 88.8% |
| Financial fixed assets28 | €98.7m | €92.6m | €92.5m | €97.9m | €93.9m | €81.1m | ▼ 13.6% |
| Affiliated companies280/1 | - | - | €92.5m | €97.9m | €93.9m | €81.1m | ▼ 13.6% |
| Participating interests280 | - | - | €92.0m | €97.9m | €93.9m | €81.1m | ▼ 13.6% |
| Amounts receivable281 | - | - | €0.5m | - | - | - | - |
| Other financial fixed assets284/8 | - | - | - | - | €0 | - | - |
| Amounts receivable and cash guarantees285/8 | - | - | - | - | €0 | - | - |
| Current assets29/58 | €13.8m | €19.7m | €17.3m | €1.2m | €0.8m | €4.4m | ▲ 453% |
| Amounts receivable after more than one year29 | - | - | €0.04m | €0.04m | €0.04m | €0.04m | = |
| Other amounts receivable291 | - | - | €0.04m | €0.04m | €0.04m | €0.04m | = |
| Amounts receivable within one year40/41 | €13.2m | €1.4m | €5.4m | €0.5m | €0.5m | €4.2m | ▲ 725% |
| Trade receivables40 | - | - | €5.0m | €0.03m | €0.04m | €0.2m | ▲ 301% |
| Other amounts receivable41 | - | - | €0.4m | €0.5m | €0.5m | €4.0m | ▲ 762% |
| Cash at bank and in hand54/58 | €0.5m | €18.0m | €11.7m | €0.5m | €0 | - | - |
| Deferred charges and accrued income490/1 | - | - | €0.2m | €0.2m | €0.2m | €0.2m | ▼ 19.5% |
| Equity and liabilities | |||||||
| Total equity and liabilities10/49 | €113.2m | €112.4m | €109.9m | €99.1m | €94.7m | €85.5m | ▼ 9.7% |
| Equity10/15 | €104.7m | €93.3m | €94.0m | €97.3m | €93.5m | €84.1m | ▼ 10.1% |
| Contributions10/11 | €98.4m | €91.4m | €91.4m | €91.4m | €91.4m | €91.4m | = |
| Capital10 | - | - | €91.4m | €91.4m | €91.4m | €91.4m | = |
| Issued capital100 | - | - | €91.4m | €91.4m | €91.4m | €91.4m | = |
| Reserves13 | €1.0m | €1.9m | €2.6m | €2.8m | €2.8m | €2.8m | = |
| Non-distributable reserves130/1 | - | - | €2.6m | €2.8m | €2.8m | €2.8m | = |
| Legal reserve130 | - | - | €2.6m | €2.8m | €2.8m | €2.8m | = |
| Profit (loss) carried forward14 | €5.3m | €0.001m | €0.001m | €3.1m | -€0.6m | -€10.0m | ▼ 1,559% |
| Amounts payable17/49 | €8.5m | €19.1m | €15.9m | €1.9m | €1.2m | €1.4m | ▲ 19.8% |
| Amounts payable after more than one year17 | €0.3m | - | - | - | - | - | - |
| Amounts payable within one year42/48 | €8.2m | €19.1m | €15.9m | €1.9m | €1.2m | €1.4m | ▲ 19.8% |
| Financial debts43 | - | - | - | €0.5m | - | - | - |
| Credit institutions430/8 | - | - | - | €0.5m | - | - | - |
| Trade debts44 | €1.1m | €0.5m | €1.6m | €0.6m | €0.6m | €0.9m | ▲ 60.9% |
| Suppliers440/4 | - | - | €1.6m | €0.6m | €0.6m | €0.9m | ▲ 60.9% |
| Taxes, remuneration and social security45 | - | - | €1.2m | €0.8m | €0.6m | €0.5m | ▼ 18.5% |
| Taxes450/3 | - | - | €0.2m | €0.03m | €0.02m | €0.2m | ▲ 929% |
| Remuneration and social security454/9 | - | - | €0.9m | €0.7m | €0.6m | €0.3m | ▼ 46.3% |
| Other amounts payable47/48 | - | - | €13.2m | - | - | - | - |
| Accrued charges and deferred income492/3 | - | - | €300 | €300 | €225 | €225 | = |
| Line | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €16.8m | €0.002m | €13.9m | €3.3m | -€3.8m | -€9.4m | ▼ 152% |
| + Depreciation and write-downs630 | €0.5m | €0.3m | €0.04m | €0.003m | €0.001m | €0.008m | ▲ 692% |
| Operating cash flow (approximation) | €17.3m | €0.3m | €13.9m | €3.3m | -€3.7m | -€9.4m | ▼ 152% |
| Investment in fixed assets (approximation) | - | - | €0.08m | -€5.4m | €4.0m | €12.8m | ▲ 224% |
| Change in cash | - | - | -€6.3m | -€11.2m | -€0.5m | - | - |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Latest 10 of 24 filings with the National Bank
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2024 | full format | 20-06-2025 | 2025-00166843 | |
| 31-12-2023 | full format | 31-07-2024 | 2024-00316483 | |
| 31-12-2022 | full format | 01-08-2023 | 2023-00309285 | |
| 31-12-2021 | full format | 28-07-2022 | 2022-20260109 | |
| 31-12-2020 | full format | 11-08-2021 | 2021-49000476 | |
| 31-12-2019 | full format | 20-08-2020 | 2020-43000145 | |
| 31-12-2018 | full format | 31-07-2019 | 2019-44100113 | |
| 31-12-2017 | full format | 28-06-2018 | 2018-25000479 | |
| 31-12-2016 | full format | 27-06-2017 | 2017-23900369 | |
| 31-12-2015 | full format | 30-06-2016 | 2016-24900414 |
Board & ownership
Directors
Directors
2 directors, 1 in day-to-day management, last change in 2023
Board 2
Jolanda Van Haarlem
Current
Director · since 10-11-2023 · 6-year term from 2023 · listed in the 2024 annual accounts, filed on 20-06-2025
Philippe van Troost
Current
Director · since 10-11-2023 · 6-year term from 2023 · listed in the 2024 annual accounts, filed on 20-06-2025
Day-to-day management 1
Philippe van Troost
Current
Day-to-day manager · appointed in the act of 12-12-2023
Statutory auditor 1
Current
Owners and capital
Shareholders
1 ownerChain of control
- Agrifirm GroupNL
- NUSCIENCE GROUP
Owners 1
- Agrifirm GroupNLconsolidating parentconsolidates
Capital transactions
Shareholders according to the deeds
Stated in the act
act of 19-11-2024 ↗
- AGRIFIRM INTERNATIONAL B.V. all shares · 100%
Capital over time
- 19-11-2024 Capital stated in the deed · €91,400,000 · 499,000 shares
Mandate history
5 people, 3 in office
- Board
- Day-to-day management
- Statutory auditor
- began earlier
| Name | Functions and periods |
|---|---|
| Jolanda Van Haarlem |
|
| Philippe van Troost |
|
| EY Bedrijfsrevisoren BV |
|
| Dirk Hordijk |
|
| WINEXPERIENCE |
|
Network & group
Holdings and subsidiaries
6 holdingsHoldings 6
Source for every holding own accounts 2024
- Nuscience Iberica s.a.u.ESsubsidiaryEquity €11.6mResult -€6.9m100%
- Nuscience Italia SrlITsubsidiaryEquity €1.5mResult €36,317100%
- Nuscience Premix International d.o.o.RSsubsidiaryEquity RSD 354.0mResult RSD 10.9m100%
- Nuscience SingaporeSGsubsidiaryEquity SGD 2.8mResult SGD 527,628100%
- Vitamex Shanghai LtdCNsubsidiaryEquity CNY 46.8mResult -CNY 10.9m100%
- Agrifirm do Brasil Nutricao Animal LtdaBRsubsidiaryEquity BRL 108.6mResult -BRL 700,44199.98%
Former holdings (2)
- Equity €14.6mResult -€5,014100%
- Equity €58.3mResult €540,026100%
Board mandates elsewhere
2 board mandatesBoard mandates of NUSCIENCE GROUPNUSCIENCE GROUP sits on their board2
2 locations
Acquisitions and mergers
1 transactionTaken over by:Nuscience Belgium
Connections & network
2 connected companiesThe connected companies are in the list below.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
Linked via shared directors
AGRI-ACTIV
Shared director
→
AGRIFIRM BELGIUM
Shared director
→
Timeline
Acts, filings and financial milestones
2025
20-06
full format · 41 days before the deadline
24-01
Gazette deed
Merger: absorbed by Nuscience BelgiumDissolution · Auditor report · Accounting effect15 points ▸
Gazette deed
Merger: absorbed by Nuscience Belgium
Dissolution · Auditor report · Accounting effect15 points ▸
- General meeting, 24-12-2024
- Merger, “fusie door overneming”, 01-01-2025 (deed in Dutch)
- Dissolution, “ontbinding zonder vereffening, ontbinding zonder vereffening” (deed in Dutch)
- Other provision, “EERSTE BESLUIT: Verzaking aan opmaak fusieverslagen - kennisname van documenten en verslagen, verzaking aan opmaak fusieverslagen en kennisname en bespreking va…” (deed in Dutch)
- Auditor report, “Gent”, EUR (deed in Dutch)
- Auditor report, “bijzonder verslag bestuursorgaan art.7:179 WVV, algemene vergadering over verrichting” (deed in Dutch)
- Other provision, “no fairness opinion, geschiktheid en opportuniteit verrichting” (deed in Dutch)
- Other provision, “laattijdige stukken, geen wezenlijke invloed op opdracht” (deed in Dutch)
- Auditor report, 20-12-2024
- Other provision, “bevoegde griffie ondernemingsrechtbank, neerlegging verslagen” (deed in Dutch)
- Other provision, “TWEEDE BESLUIT:Wijzigingen in de vermogenstoestand” (deed in Dutch)
- Other provision, “DERDE BESLUIT:Verzaking aan tussentijdse cijfers” (deed in Dutch)
- The act holds 3 more points.
2024
31-12
Financial
Weakest financial yearnet -€9.4m
The net result drops to -€9.4m, the lowest from 2018 to 2024.
31-12
Financial
Liquidity more than quadruplescurrent ratio 3.06
The current ratio rises from 0.66 to 3.06.
31-12
Gazette deed
Reappointment: EY Bedrijfsrevisoren BV (statutory auditor)Permanent representatives: Line Vyvey and Francis Boelens4 points ▸
Gazette deed
Reappointment: EY Bedrijfsrevisoren BV (statutory auditor)
Permanent representatives: Line Vyvey and Francis Boelens4 points ▸
- Board meeting, 11-12-2024
- Auditor reappointment, EY Bedrijfsrevisoren BV (statutory auditor)
- Permanent representative, Line Vyvey
- Permanent representative, Francis Boelens
19-11
Gazette deed
Merger proposal: to be absorbed by NUSCIENCE BELGIUMPermanent representatives: Tom Lambert and Jolanda van Haarlem · Capital · Accounting effect28 points ▸
Gazette deed
Merger proposal: to be absorbed by NUSCIENCE BELGIUM
Permanent representatives: Tom Lambert and Jolanda van Haarlem · Capital · Accounting effect28 points ▸
- Merger, “fusie door overneming”, EUR (deed in Dutch)
- Capital, €91,400,000
- Other provision, “registerinschrijving, rechtspersonenregister te Gent,afdeling Gent” (deed in Dutch), mentioned 2 times in the deed
- Board composition, LEXTRA BV (director), mentioned 2 times in the deed
- Permanent representative, Tom Lambert, mentioned 2 times in the deed
- Board composition, Jolanda van Haarlem (director)
- Board composition, Philippe van Troost (director), mentioned 2 times in the deed
- Capital, €41,542,053.35
- Board composition, “bestuurder” (deed in Dutch)
- Permanent representative, Jolanda van Haarlem
- Other provision, “waarderingsgrondslag voorlopige ruilverhouding, boekhoudkundige eigenvermogenswaarde” (deed in Dutch)
- Accounting effect, 01-01-2025
- The act holds 16 more points.
29-08
Gazette deed
Reappointment: EY Bedrijfsrevisoren BV (statutory auditor)Permanent representatives: Boelens Francis and Tom Lambert5 points ▸
Gazette deed
Reappointment: EY Bedrijfsrevisoren BV (statutory auditor)
Permanent representatives: Boelens Francis and Tom Lambert5 points ▸
- General meeting, 28-06-2024
- Auditor reappointment, EY Bedrijfsrevisoren BV (statutory auditor)
- Permanent representative, Boelens Francis
- Director in office, Lextra BV (director)
- Permanent representative, Tom Lambert
31-07
full format · on the deadline day
2023
12-12
Gazette deed
Resignations: Winexperience BV (director) and Dirk Hordijk (director)Permanent representatives: Johan De Schepper and Tom Lambert · Appointments: Jolanda Van Haarlem (director) and Philippe van Troost (director) · Board rule14 points ▸
Gazette deed
Resignations: Winexperience BV (director) and Dirk Hordijk (director)
Permanent representatives: Johan De Schepper and Tom Lambert · Appointments: Jolanda Van Haarlem (director) and Philippe van Troost (director) · Board rule14 points ▸
- General meeting, 08-11-2023
- Director resignation, Winexperience BV (director)
- Permanent representative, Johan De Schepper
- Director appointment, Jolanda Van Haarlem (director)
- Director resignation, Dirk Hordijk (director)
- Director appointment, Philippe van Troost (director)
- Board rule, 3
- Board composition, Lextra BV (director)
- Board composition, Jolanda Van Haarlem (director)
- Board composition, Philippe van Troost (director)
- Permanent representative, Tom Lambert
- Board meeting, 10-11-2023
- The act holds 2 more points.
01-08
full format · 1 day late
2022
17-08
Gazette deed
Reappointment: Dirk Hordijk (director)Permanent representatives: Tom Lambert and Johan De Schepper · Board rule8 points ▸
Gazette deed
Reappointment: Dirk Hordijk (director)
Permanent representatives: Tom Lambert and Johan De Schepper · Board rule8 points ▸
- General meeting, 30-06-2022
- Director reappointment, Dirk Hordijk (director)
- Board rule, 3
- Board composition, Dirk Hordijk (director)
- Board composition, Lextra BV (director)
- Board composition, Winexperience BV (director)
- Permanent representative, Tom Lambert
- Permanent representative, Johan De Schepper
28-07
full format · 3 days before the deadline
Show earlier events
2021
11-08
full format · 11 days late
2020
20-08
full format · 20 days late
2019
31-07
full format · on the deadline day
2018
28-06
full format · 33 days before the deadline
2017
27-06
full format · 34 days before the deadline
2016
30-06
full format · 31 days before the deadline
2002
06-09
37 publications in the Belgian Official Gazette, the last on 24-01-2025
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Inactive
Absorbed by Nuscience Belgium in January 2025
NUSCIENCE GROUP is no longer in the KBO register. Nuscience Belgium took it over in a merger by absorption, published in the Belgian Official Gazette on 19 February 2025.
- Status
- Inactive
- Reason
- Merger by absorptionBelgian Official Gazette, 19 February 2025 · act
- Absorbed by
- Nuscience Belgium · 0412.718.370
- Last annual accounts
- financial year to 31 December 2024
- Last registered office
- Booiebos 5, 9031 Drongen (Gent)as published on 24 January 2025
- Legal form
- Public limited company
- First annual accounts
- financial year 2003
Purpose, financial year and meetings according to the articles of association
- Registered office clauseThe articles name the region of the registered office. The language of official documents depends on that region, among other things.
- “Boojebos 5,9031 Gent”
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- “Het boekjaar van de vennootschap gaat in op 1 januari en eindigt op 31 december van datzelfde kalenderjaar. De gewone algemene vergadering…”
Articles of association, deed of 19-11-2024 (in Dutch)